Nanollose Ltd (ASX:NC6) on 16 April 2018, lodged a Prospectus with ASIC and ASX, seeking to raise up to approximately $187,500 by a non-renounceable rights offer of up to approximately 18,749,999 entitlement options on the basis of 1 entitlement option for every 4 shares held at an issue price of 1 cent per entitlement option.
Nanollose Limited (ASX:NC6) is pleased to announce that the Company will be presenting at the TechKnow Invest Roadshow in Sydney on Tuesday 10th April 2018 (today) and Melbourne on Thursday 12th April 2018.
Nanollose Limited (ASX:NC6) is pleased to announce that as the Company enters a new phase of commercialisation and development, Dr Wayne Best will increase his involvement across research and development and assist in the effort to prioritise and convert numerous opportunities currently being presented to the Company.
Nanollose Limited (ASX:NC6) is pleased to announce that the Company has signed a non-binding Memorandum of Understanding (MoU) with Indonesian food producer, PT Supra Natami Utama (PT SNU).
The board of Queensland Bauxite Limited (ASX:QBL) is pleased to update the market on developments in the drug development strategy for its subsidiary, Medical Cannabis Limited. MCL, in conjunction with Certara, a pharmaceutical consulting firm, have developed a drug development strategy for the distribution of Canntab XR medication in the Australian market.
The Board of Queensland Bauxite (ASX:QBL) is pleased to advise that it has cleared the company's outstanding debt by way of share issue.
The Directors present their report on Queensland Bauxite Limited, consisting of Queensland Bauxite Limited (ASX:QBL) and the entities it controlled at the end of or during the half-year ended 31 December 2017.
